CovX-Bodies

Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges

Volumn , Issue , 2013, Pages 571-582

  Bhat, Abhijit ^a   Laurent, Olivier ^a   Lappe, Rodney ^a  

^a PFIZER INC   (United States)

Author keywords

Bispecific antibody; CovX bodies; CovX Body technology; CVX 241 CVX 343; Scaffold antibody

Indexed keywords

EID: 84886197573     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118354599.ch38     Document Type: Chapter

References (34)

1. An Z. (2009) Therapeutic Monoclonal Antibodies. From Bench to Clinic. John Wiley and Sons, Inc., New Jersey, 711-762.
2. Wirsching P, Ashley JA, Lo CL, Janda KD, Lerner RA. (1995) Reactive immunization. Science 270, 1775-1782.
3. Wagner J, Lerner RA, Barbas CF, III. (1995) Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes. Science 270, 1797-1780.
4. Barbas CF. III, Heine A, Zhong G, Hoffman T, Gramatikova S, Björnested R, et al. (1997) Immune versus natural selection: antibody aldolases with enzymic rates but broader scope. Science 278, 2085-2092.
5. RaderC, Sinha SC, PopkovM, LernerRA, BarbasCF. III. (2003) Chemically programmed monoclonal antibodies for cancer therapy: Adaptor immunotherapy based on a covalent antibody catalyst. Proc. Natl. Acad. Sci.USA 100(9), 5396-5400.
6. Doppalapudi VR, Tryder N, Li L, Aja T, Griffith D, Liao F, et al. (2007) Chemically programmed antibodies: endothelin receptor targeting CovX-Bodies. Bioorg. Med. Chem. Lett. 17, 501-506.
7. Liu D, Wood L, Wheeler W, Zhao J, Griffith D, Bradshaw C, et al. (2006) CCR5 Targeting CovX-Bodies. 30th National Medicinal Chemistry Meeting, June 25-29, University of Washington, Seattle.
8. Rader C,TurnerJM,Heine A,Shabat D,Sinha S,WilsonIA, et al. (2003) A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy. J.Mol. Biol. 332, 889-899.
9. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D,Wong WL, et al. (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89 (10), 5434-5441.
10. de Wildt RM, Hoet RM, van Venrooij WJ, Tomlinson IM, Winter G. (1999) Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire. J. Mol. Biol. 285(3), 895-901.
11. de Wildt RM, Mundy CR, Gorick BD, Tomlinson IM. (2000) Antibody arrays for high-throughput screening of antibodyantigen. Nat. Biotechnol. 18(9), 989-994.
12. Kyte J, Doolittle RF. (1982) A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157(1), 105-132.
13. Rosen CA, HaseltineWA. (2003) Albumin Fusion Proteins for Prolonged Shelf-Life of Therapeutic Proteins. PCT Int. Appl. WO 2003059934.
14. Leger R, Thibaudeau K, Robitaille M, Quraishi O, van Wyk P, Bousquet-Gagnon N, et al. (2004) Identification of CJC-1131- albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog. Bioorg. Med. Chem. Lett. 14(17), 4395-4398.
15. Kim B, Zhou J, Martin B, Carlson OD, Maudsley S, Greig NH, et al. (2010) Transferrin fusion technology: A novel approach to prolonging biological half-life of insulinotroic peptides. J. Pharmacol. Exp. Ther. 334(3), 682-692.
16. Sutherland S. (2004) Peptibodies: The new cool technology. Drug Discov. Today 9(16), 683.
17. Huang H, Bhat A, Woodnutt G, Lappe R. (2010) Targeting the ANGPT-TIE2 pathway in malignancy. Nat. Rev. Cancer 10(8), 575-585.
18. Huang H, Lai J, Do J, Liu D, Li L, Del Rosario J, et al. (2011) Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin. Cancer Res. 17(5), 1001-1011.
19. Rosen LS, Mendelson DS, Cohen RB, Gordon MS, Goldman JW, Bear IK, et al. (2010). First-in-Human Dose-Escalation Safety and PK Trial of a Novel Intravenous Humanized Monoclonal CovX Body Inhibiting Angiopoietin 2 [Abstract]. J. Clin. Oncol. 28:15s, Abstract 2524.
20. Cheng HM. (2007) Dynamic contrast enhanced magnetic resonance imaging in oncology drug development. Curr. Clin. Pharmacol. 2(2), 111-122.
21. Fischer N, Leger O. (2007) Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 74, 3-14.
22. Hagemeyer CE, von Zur Muhlen C, von Elverfeldt D, Peter K. (2009) Single-chain antibodies as diagnostic tools and therapeutic agents. Thromb. Haemost. 101, 1012-1019.
23. Robinson MK, Hodge KM, Horak E, Sundberg A L, Russeva M, Shaller CC, et al. (2008) Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br. J. Cancer 99, 1415-1425.
24. Hudson PJ, Kortt AA. (1999) High avidity scFv multimers, diabodies and triabodies. J. Immunol. Methods 231, 177-189.
25. Kipriyanov SM. (2009) Generation of bispecific and tandem diabodies. Methods Mol. Biol. 562, 177-193.
26. Bostrom J, Yu S, Kan D, Appleton BA, Lee CV, Billeci K, et al. (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614.
27. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, et al. (2007) Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat. Biotechnol. 25, 1290-1297.
28. Constantinou A, Epenetos AA, Hreczuk-Hirst D, Jain S, Wright M, Chester KA, et al. (2009). Site-specific polysialylation of an antitumor single-chain Fv fragment. Bioconjug. Chem. 20(5), 924-931.
29. Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, et al. (2010) Chemical generation of bispecific antibodies. Proc. Natl. Acad. Sci. USA 107(52), 22611-22616.
30. Carmeliet P. (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl. 3), 4-10.
31. Ferrara N, Gerber HP, LeCouter J. (2003) The biology of VEGF and its receptors. Nat. Med. 9, 669-676.
32. Moon WS, Rhyu KS, Kang MJ, Lee DG, Yu HC, Yeum JH, et al. (2003) Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Modern Pathol. 16, 552-557.
33. Ochiumi T, Tanaka S, Oka S, Hiyama T, Ito M, Kitadai Y, et al. (2004) Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma. Int. J. Oncol. 24, 539-547.
34. Huang J, Rolzin P, Osothprarop T, Ishino T,Wiese J, Retting K, et al. (2011) CVX-343 A long acting FGF-21 CovX-Body demonstrates prolonged antidiabetic efficacy in diabetic mouse models. 71stAmerican Diabetes Association Scientific Sessions, June 23-28, San Diego CA. 582 CovX-BODIES